Study of FYU-981 in Hyperuricemia With or Without Gout
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is exploratory investigation of safety and efficacy (dose response
and optimal dose according to the percent reduction from baseline in serum urate level at the
final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout
for 8 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 4 weeks)
by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel
group comparison.